We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

130 hedge funds and large institutions have $360M invested in Akebia Therapeutics in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 42 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

914% more call options, than puts

Call options by funds: $8.21M | Put options by funds: $810K

2% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 42

3.9% less ownership

Funds ownership: 75.42% → 71.53% (-3.9%)

10% less funds holding

Funds holding: 145 → 130 (-15)

15% less capital invested

Capital invested by funds: $423M → $360M (-$63M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

47% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 32

Holders
130
Holders Change
-15
Holders Change %
-10.34%
% of All Funds
2.97%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
17
Increased
43
Reduced
42
Closed
32
Calls
$8.21M
Puts
$810K
Net Calls
+$7.41M
Net Calls Change
-$930K

Top Buyers

1
ACM
Abrams Capital Management
Massachusetts
+$10M
2
ClearBridge Investments
ClearBridge Investments
New York
+$9.09M
3
Morgan Stanley
Morgan Stanley
New York
+$4.44M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$4.06M
5
Citadel Advisors
Citadel Advisors
Florida
+$3.32M

Top Sellers

1
EAM
Eagle Asset Management
Florida
-$28.2M
2
CTA
Carillon Tower Advisers
Florida
-$20.6M
3
LCM
Laurion Capital Management
New York
-$3.72M
4
American Century Companies
American Century Companies
Missouri
-$3.44M
5
AIM
Alambic Investment Management
California
-$1.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$46.5M +$2.27M +253,811 +5%
NCM
2
Nantahala Capital Management
Connecticut
$41.7M +$1.8M +201,100 +4%
NHAS
3
Novo Holdings A/S
Denmark
$27.4M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$22.6M -$159K -17,771 -0.7%
PA
5
Perceptive Advisors
New York
$21.6M +$2.09M +234,121 +11%
State Street
6
State Street
Massachusetts
$20.1M +$3.14M +350,738 +18%
Morgan Stanley
7
Morgan Stanley
New York
$16.7M +$4.44M +496,069 +36%
Renaissance Technologies
8
Renaissance Technologies
New York
$15.7M -$873K -97,629 -5%
ACM
9
Abrams Capital Management
Massachusetts
$9.88M +$10M +1,119,286 New
ClearBridge Investments
10
ClearBridge Investments
New York
$8.98M +$9.09M +1,016,397 +787,905%
Citadel Advisors
11
Citadel Advisors
Florida
$8.76M +$3.32M +371,440 +60%
First Manhattan
12
First Manhattan
New York
$7.08M +$2.11M +236,300 +42%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$5.96M -$1.25M -139,277 -17%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$5.63M +$470K +52,556 +9%
Northern Trust
15
Northern Trust
Illinois
$5.6M +$190K +21,209 +3%
DCM
16
DAFNA Capital Management
California
$5.53M +$134K +15,000 +2%
MWNA
17
Marshall Wace North America
New York
$5.13M – – –
Marshall Wace
18
Marshall Wace
United Kingdom
$4.76M -$1.74K -195 -0%
TCIM
19
TIAA CREF Investment Management
New York
$4.29M +$172K +19,263 +4%
AG
20
Artal Group
Luxembourg
$4.19M – – –
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$4.01M +$4.06M +453,627 New
Wellington Management Group
22
Wellington Management Group
Massachusetts
$3.62M -$1.4M -156,024 -28%
Deutsche Bank
23
Deutsche Bank
Germany
$3.17M +$1.75M +195,825 +120%
Charles Schwab
24
Charles Schwab
California
$3.09M -$294K -32,890 -9%
Jacobs Levy Equity Management
25
Jacobs Levy Equity Management
New Jersey
$2.92M +$486K +54,299 +20%
1
2 3 4 5

AKBA Hedge Fund Activity: Q3 2018 in Review

130 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2018, worth a combined $360M — down 15% from $423M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of AKBA and 17 opened new positions — a net loss of 15 holders — while 42 trimmed existing stakes and 43 added.

The largest buyer was Abrams Capital Management, opening a new position worth an estimated $10M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $28.2M sold.

  • 130 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2018, down from 145 in Q2 2018.
  • Funds reported $360M of Akebia Therapeutics stock for Q3 2018, down 15% quarter-over-quarter.
  • 17 funds opened new Akebia Therapeutics positions in Q3 2018 and 32 closed out, a net change of -15 holders.
  • The largest Akebia Therapeutics buyer in Q3 2018 was Abrams Capital Management, an estimated $10M added.
  • The largest Akebia Therapeutics seller in Q3 2018 was Eagle Asset Management, an estimated $28.2M sold.

Based on aggregated 13F filings for Q3 2018.